---
aliases: [NVS]
---
#actor #pharma #switzerland #public

**Novartis** — Swiss pharma focused. Entresto, Cosentyx, Kisqali. Spun off Sandoz (generics).

---

## Why Novartis matters

| Metric | Value |
|--------|-------|
| Ticker | NVS (ADR) |
| Market cap | ~$220B |
| Revenue | ~$50B |
| HQ | Basel, [[Switzerland]] |
| Focus | Pure-play innovative pharma |

---

## Post-Sandoz structure

| Event | Date |
|-------|------|
| Sandoz spinoff | Oct 2023 |
| Focus now | Innovative medicines only |
| Divested | Generics, biosimilars |

---

## Key drugs

| Drug | Indication | Status |
|------|------------|--------|
| **Entresto** | Heart failure | Blockbuster |
| **Cosentyx** | Immunology | Growing |
| **Kisqali** | Breast cancer | Growing rapidly |
| **Kesimpta** | Multiple sclerosis | Growing |
| **Pluvicto** | Prostate cancer | Radioligand |
| **Zolgensma** | Gene therapy (SMA) | High-value |

---

## Therapeutic areas

| Area | Key assets |
|------|------------|
| **Cardiovascular** | Entresto, Leqvio |
| **Immunology** | Cosentyx |
| **Oncology** | Kisqali, Pluvicto |
| **Neuroscience** | Kesimpta |
| **Gene therapy** | Zolgensma |

---

## Radioligand therapy

| Asset | Status |
|-------|--------|
| Pluvicto | Approved prostate |
| Pipeline | Multiple tumors |
| Advantage | Targeted radiation |

**Strategic bet:** Radioligand as differentiated oncology platform.

---

## Investment case

**Bull:**
- Entresto heart failure dominance
- Kisqali breast cancer growth
- Radioligand platform
- Post-Sandoz focus
- Strong pipeline

**Bear:**
- Cosentyx competition (IL-17)
- [[Patent cliffs]] coming
- Gene therapy economics
- [[Swiss franc]] exposure
- Mature growth profile

---

## Quick stats

| Metric | Value |
|--------|-------|
| Ticker | NVS |
| Revenue | ~$50B |
| Focus | Innovative pharma |
| Key drug | Entresto |

---

## Related

- [[Biopharma]] — sector
- [[Roche]] — Swiss peer
- [[Eli Lilly]] — pharma peer
- [[Isomorphic Labs]] — $3B deal

---

## Sources

- Company filings

*Created 2026-01-09*
